Group 1: Dongcheng Pharmaceutical - Dongcheng Pharmaceutical reported a 2.6% decline in revenue to 1.384 billion yuan for the first half of 2025, with net profit attributable to shareholders decreasing by 20.70% to 88.6525 million yuan [1] - The nuclear medicine segment generated sales of 503 million yuan, a year-on-year increase of 0.78%, with key product F-FDG achieving revenue of 212 million yuan, up 8.72% due to increased sales volume [1] - The raw material drug segment saw sales of 611 million yuan, down 7.02%, with heparin raw material revenue falling by 8.90% to 440 million yuan due to price declines, while chondroitin sulfate product revenue rose by 4.26% to 165 million yuan [1] Group 2: Haosen Pharmaceutical - Haosen Pharmaceutical experienced a 14.93% increase in revenue to 242 million yuan for the first half of 2025, with net profit rising by 4.74% to 60.7942 million yuan [2] - The raw material drug and intermediate business segments reported sales growth of 13.94% and 29.24% respectively, driving overall performance improvement [2] - The company achieved a significant 53.04% increase in overseas sales, supported by a strong focus on product quality and service, leading to an expanded market share [2] Group 3: Fuhong Hanlin - Fuhong Hanlin's application for the market registration of HLX04-O, a recombinant humanized monoclonal antibody injection for wet age-related macular degeneration, has been accepted by the National Medical Products Administration [3] - Currently, there are no approved products for this indication in China, highlighting a potential market opportunity [3] Group 4: Huazhong Medicine - Huazhong Medicine announced plans to invest up to 87 million yuan to establish a biopharmaceutical industry fund, targeting a total fundraising goal of 500 million yuan [5] - The fund aims to optimize the company's strategic layout in synthetic biology and enhance innovation incubation and product commercialization [6] Group 5: Xingqi Eye Medicine - Xingqi Eye Medicine has initiated the Phase II clinical trial for voriconazole eye drops, targeting fungal keratitis, a common cause of blindness in China [7] - Voriconazole is noted for its broad antimicrobial spectrum and low toxicity, with the trial designed to explore its efficacy and safety in patients [7] Group 6: East China Pharmaceutical - East China Pharmaceutical has signed an exclusive commercialization agreement for VC005 with Jiangsu Weikail, committing to an initial payment of 50 million yuan and potential milestone payments up to 180 million yuan [8] - The agreement grants East China exclusive rights for the oral formulation of VC005 in mainland China, indicating a strategic move to expand its product portfolio [8]

Core Viewpoint - China Resources Pharmaceutical (03320) announced plans to establish a fund with an expected scale of 500 million yuan, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [2][2]. Company Summary - The fund will involve China Resources Pharmaceutical (Shantou), China Resources Double Crane, Double Crane (Beijing), and China Resources Pharmaceutical Investment, along with Hanwei Huayou Shantou and other interested partners [2][2]. - China Resources Pharmaceutical plans to commit a total investment of no more than 123 million yuan, accounting for approximately 24.6% of the total committed capital of the fund [2][2]. - The fund is expected to be managed by Shenzhen China Resources Capital and will not be accounted as a subsidiary of China Resources Pharmaceutical upon establishment [2][2]. Related Parties - Hanwei Huayou Shantou is a wholly-owned subsidiary of China Resources Investment (Tianjin), which is ultimately held by China Resources Group, the controlling shareholder of China Resources Pharmaceutical, thus constituting a related party transaction [2][2]. Business Overview - Established in 2007, China Resources Pharmaceutical operates in the manufacturing and commercial distribution of pharmaceuticals, health products, and medical devices [2][2]. - The company owns several subsidiaries, including China Resources Pharmaceutical Commercial Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd., China Resources Jiangzhong Pharmaceutical Group Co., Ltd., and Dong'e Ejiao Co., Ltd. [2][2]. Financial Performance - In 2024, China Resources Pharmaceutical achieved operating revenue of 257.673 billion yuan, representing a year-on-year growth of 5.3% [2][2]. - The net profit attributable to the parent company was 3.351 billion yuan, showing a year-on-year decline of 13.06% [2][2].

公司本次以自有资金出资参与设立该基金，不会对公司的持续经营能力、损益及资产状况产生重大影 响。本次交易完成后，公司所占该基金份额为4%，不构成控制及重大影响，不会新增控股子公司，不 会导致公司合并报表范围变化。 证券时报记者 孙宪超 华润双鹤（600062）7月17日晚公告，公司拟与普通合伙人华润医药（成都）企业管理合伙企业（有限 合伙）（暂定名，以工商核准名为准）及华润医药投资有限公司等10家有限合伙人共同投资设立华润医 药（成都）创新投资基金合伙企业（有限合伙）（暂定名，以工商核准名为准）。该基金目标募集规模 为10亿元，深圳市华润资本股权投资有限公司为基金管理人。公司作为有限合伙人拟以自有资金出资 4000万元，占基金总出资额的4%。 据介绍，华润医药（成都）企业管理合伙企业（有限合伙）、华润医药投资有限公司、华润博雅生物制 药集团股份有限公司等均为受中国华润控制的法人及组织，与华润双鹤受同一最终控制方控制，根据相 关规定，本次交易构成关联交易。 华润双鹤表示，本次参与投资设立该基金，旨在优化公司战略布局，持续推进创新转型，提高优质资源 获取与配置能力，同时获得一定的投资收益，提升公司中长期发展与盈利能 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润双鹤"或"公司")拟投资设立华润双鹤生物 医药产业基金(呼和浩特)投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华润双鹤产 业基金"或"该基金")，基金目标募集规模为5亿元人民币，公司及全资子公司双鹤(北京)生物技术有限公 司(以下简称"双鹤生物")拟以自有资金出资不超过8,700万元人民币，占基金总出资额的比例不超过 17.40%。 ● 本次交易构成关联交易，不构成重大资产重组。 ● 本次交易金额超过3,000万元，未超过公司2024年度经审计净资产的5%，已经董事会审议批准，无需 提交股东会审议。 ● 过去12个月内，除日常关联交易及本次交易外，公司拟以自有资金4,000万元人民币与华润医药投资 有限公司等11家合伙人共同投资设立华润医药(成都)创新投资基金合伙企业(有限合伙)(以下简称"华润 医药产业投资基金二期")，基金目标募集规模为10亿元人民币，公司出资比例为4.00%。除前述交 ...

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-065 华润双鹤药业股份有限公司 关于设立华润双鹤产业基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： ? 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润 双鹤"或"公司")拟投资设立华润双鹤生物医药产业基金(呼和浩特) 投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华 润双鹤产业基金"或"该基金")，基金目标募集规模为 5 亿元人民 币，公司及全资子公司双鹤(北京)生物技术有限公司(以下简称"双鹤 生物")拟以自有资金出资不超过 8,700 万元人民币，占基金总出资额 的比例不超过 17.40%。 ? 本次交易构成关联交易，不构成重大资产重组。 ? 本次交易金额超过 3,000 万元，未超过公司 2024 年度经审计 净资产的 5%，已经董事会审议批准，无需提交股东会审议。 ? 过去 12 个月内，除日常关联交易及本次交易外，公司拟以自 有资金 4,000 万元人民币与华润医药投资有限公司等 11 ...

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Core Viewpoint - China Resources Double Crane (华润双鹤) is strategically investing in synthetic biology, establishing a biopharmaceutical industry fund with a target of 500 million RMB to enhance its investment capabilities in key areas like synthetic biology and health products [2][4]. Group 1: Investment and Strategic Direction - On August 12, China Resources Double Crane announced plans to establish a biopharmaceutical industry fund with a target fundraising scale of 500 million RMB, with the company and its wholly-owned subsidiary contributing up to 87 million RMB, accounting for no more than 17.4% of the total fund [2]. - The company has identified synthetic biology as one of its strategic development directions and has established a comprehensive "R&D + pilot test + industrialization" three-tier system, including a synthetic biology industrialization platform in Hohhot [2][4]. - The establishment of the fund aims to optimize the company's strategic layout in synthetic biology and other key areas, leveraging synergies with Hohhot's industrial development to enhance investment methods in synthetic biology [2]. Group 2: Financial Performance - In the first quarter of 2025, China Resources Double Crane achieved revenue of 3.079 billion RMB and a net profit attributable to shareholders of 507 million RMB [3]. Group 3: Historical Context and Acquisitions - In 2022, China Resources Double Crane invested 500 million RMB to acquire Shenzhou Biology, establishing it as a base for synthetic biology industrialization [4]. - In 2023, the company established the China Resources Double Crane Synthetic Biology Research Institute, focusing on talent acquisition and the simultaneous construction of a pilot test base [4]. Group 4: Technological Development - The small-scale testing platform has been largely completed, focusing on core capabilities such as molecular modification, high-throughput screening, strain validation, and enzyme engineering [6]. - The company is prioritizing the construction of pilot fermentation workshops to enhance its pilot conversion capabilities [6]. Group 5: Market Positioning - Shenzhou Biology is recognized as the world's second-largest supplier of coenzyme Q10, holding a stable global market share of 30% [7]. - The chairman of the company emphasized that the focus on synthetic biology is primarily around health products, aiming to enhance the competitiveness of existing core products through synthetic biology technology [7].

Core Viewpoint - China Resources Double Crane announced the establishment of a biopharmaceutical industry fund with a target fundraising scale of 500 million RMB, aiming to enhance its strategic layout in synthetic biology and promote innovation and commercialization of products and technologies [1][4]. Group 1: Fund Details - The fund, named China Resources Double Crane Biopharmaceutical Industry Fund (Hohhot), will have a total investment of 50 million RMB, with the company and its wholly-owned subsidiary contributing up to 87 million RMB, accounting for no more than 17.40% of the total fund [1][4]. - The fund's partners include various entities, with China Resources Double Crane Pharmaceutical Co., Ltd. contributing 83 million RMB, representing 16.60% of the total fund [3]. Group 2: Strategic Objectives - The establishment of the fund is part of the company's strategic direction towards synthetic biology, aiming to leverage synergies with Hohhot's industrial development and enhance investment methods in key areas [4]. - The fund is expected to facilitate innovation incubation, accelerate product and technology collaboration, and secure commercial rights for products [4].

8月12日晚，华润双鹤（600062）公告，拟投资设立华润双鹤生物医药产业基金，基金目标募集规模为5 亿元。华润双鹤及全资子公司双鹤生物拟以自有资金出资不超过8700万元，占基金总出资额的比例不超 过17.40%。 华润双鹤表示，合成生物的应用领域非常广泛，公司合成生物承担了国资委重点任务，将积极参与国家 标准制定，未来将是公司的重点发展方向之一。同时，围绕八个专科领域进行拓展，公司已储备一些高 质量内涵的特色专科领域(如眼科、儿科、精神/神经)，还将围绕消化科等领域加速寻源，通过双方的赋 能，确保未来实现更好的成长性。 此外，对创新孵化类企业或产品，华润双鹤将以商业化合作和产业化合作为基础进行战略性投资，选择 BD产品的重要标准是该产品在中国市场具备一定规模的发展潜力，能弥补华润双鹤产品管线的不足， 在推进BD的同时，可能与BD产品所属企业开展股权层面合作，未来通过产品管线不断商业化，并入公 司现有板块。 值得一提的是，早在2017年10月，华润双鹤与华润医药股权投资基金管理(汕头)有限公司等5家普通合 伙人、华润医药投资有限公司等8家有限合伙人共同设立华润医药产业投资基金合伙企业(有限合伙)， 该投资基金 ...